CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Status:
Recruiting
Trial end date:
2023-01-31
Target enrollment:
Participant gender:
Summary
This phase II trial investigates how well CPX-351 and ivosidenib work in treating patients
with acute myeloid leukemia or high-risk myelodysplastic syndrome that has IDH1 mutation. The
safety of this drug combination will also be studied. IDH1 is a type of genetic mutation
(change). Chemotherapy drugs, such as CPX-351, work in different ways to stop the growth of
cancer cells, either by killing the cells, by stopping them from dividing, or by stopping
them from spreading. Ivosidenib may stop the growth of cancer cells by blocking some of the
enzymes needed for cell growth. The purpose of this trial is to learn if CPX-351 in
combination with ivosidenib can help to control IDH1-mutated acute myeloid leukemia or
high-risk myelodysplastic syndrome.